Clinical TrialJun 9, 2026, 07:46 AM
Actuate's Elraglusib Enters BEACON2 Trial for Neuroblastoma
AI Summary
Actuate Therapeutics announced that its lead investigational drug, elraglusib, will be evaluated in the BEACON2 clinical trial for children with relapsed and refractory neuroblastoma. This international, multi-arm, multi-stage Phase 1/2 platform study will initially assess elraglusib in combination with dinutuximab beta plus chemotherapy in a dose confirmation cohort. The inclusion in BEACON2 is a significant milestone, supported by compelling preclinical evidence, early clinical evidence including a complete response in a neuroblastoma patient, and FDA Rare Pediatric Disease designation.
Key Highlights
- Actuate's elraglusib will be evaluated in the BEACON2 clinical trial for relapsed and refractory neuroblastoma.
- BEACON2 is an international, multi-arm, multi-stage Phase 1/2 platform study.
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy.
- The initial dose confirmation cohort will enroll up to 20 patients.
- A neuroblastoma patient achieved a complete response in a prior Phase 1 study of elraglusib.
- Elraglusib received FDA Rare Pediatric Disease designation for neuroblastoma.
- BEACON2 is sponsored by the Cancer Research UK Clinical Trials Unit, University of Birmingham.
- The trial is active across 14 UK sites and plans to expand to up to 60 international sites.
Price Impact
More from ACTU